Livmarli helps Alagille patients stop other anti-itch meds in real world
About one year of treatment with Livmarli (maralixibat) allows about a third of patients with Alagille syndrome to stop at least one other…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
Benefits of Livmarli for cholestasis sustained up to 2 years: Trial data
Up to two years of daily treatment with Livmarli (maralixibat) controlled itch and reduced blood levels of bile acids and bilirubin, two markers of…
Namodenoson study for severe fatty liver disease cleared for US
Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral treatment candidate namodenoson in people…
Analyses on volixibat trial data in PSC, PBC slated for June
Interim analyses of data from Phase 2 clinical trials testing Mirum Pharmaceuticals’ oral therapy candidate volixibat in people with itch, or pruritus, due to…
Livmarli benefits seen across PFIC types, trial data show
Treatment with Livmarli (maralixibat) leads to significant clinical benefits for people with progressive familial intrahepatic cholestasis (PFIC) across a wide range of disease…
Chronic hepatitis B undertreated globally, real-world study finds
Global rates for evaluating chronic hepatitis B and starting appropriate treatment are lower than they should be, especially among women and Asian minorities living…
Bylvay eases itch, signs of liver damage in Alagille, trial data show
Daily treatment with Bylvay (odevixibat) safely and effectively eases itching and lowers blood bile acid levels, a sign of liver damage, in children and adolescents…
Hepatitis Awareness Month promotes screening, vaccination
Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise awareness of viral hepatitis…
Gilead awards $4M funding to hepatitis B, C, D elimination projects
Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…
FXR314 well tolerated, lowers liver fat, Phase 2 MASH trial shows
FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…